Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 문영철 | * |
dc.date.accessioned | 2018-12-14T16:31:14Z | - |
dc.date.available | 2018-12-14T16:31:14Z | - |
dc.date.issued | 2018 | * |
dc.identifier.issn | 1083-8791 | * |
dc.identifier.other | OAK-22433 | * |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/247856 | - |
dc.description.abstract | This prospective study evaluated the efficacy and toxicity of intravenous busulfan and melphalan as a conditioning regimen for autologous stem cell transplantation (ASCT) in patients with multiple myeloma (MM). A total of 99 patients with MM, enrolled between January 2013 and March 2016, received intravenous busulfan (9.6 mg/kg) and melphalan (140 mg/m2) before ASCT. The median time to transplant was 6.2 months, and 90 (90.9%) patients underwent ASCT within 12 months of the diagnosis. The overall response rate after ASCT was 94.0%, including 43.5% with a stringent complete response/complete response, 27.3% with very good partial response, and 23.2% with partial response. The most common severe nonhematologic toxicity (grade 3 to 4) was infection (26.3%) and stomatitis (15.2%). Three (3.2%) patients developed veno-occlusive disease. No treatment-related mortality was observed. After a median follow-up of 26.1 months, the median progression-free survival was 27.2 months (range, 13.0 to 41.4 months) and median overall survival was not reached. In conclusion, a conditioning regimen of intravenous busulfan and melphalan was effective and tolerable. ClinicalTrials.gov. number: NCT01923935 © 2018 The American Society for Blood and Marrow Transplantation | * |
dc.language | English | * |
dc.publisher | Elsevier Inc. | * |
dc.subject | Autologous transplantation | * |
dc.subject | Intravenous busulfan | * |
dc.subject | Melphalan | * |
dc.subject | Multiple myeloma | * |
dc.title | Phase 2 Study of an Intravenous Busulfan and Melphalan Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma (KMM150) | * |
dc.type | Article | * |
dc.relation.issue | 5 | * |
dc.relation.volume | 24 | * |
dc.relation.index | SCIE | * |
dc.relation.index | SCOPUS | * |
dc.relation.startpage | 923 | * |
dc.relation.lastpage | 929 | * |
dc.relation.journaltitle | Biology of Blood and Marrow Transplantation | * |
dc.identifier.doi | 10.1016/j.bbmt.2018.01.004 | * |
dc.identifier.wosid | WOS:000433400000007 | * |
dc.identifier.scopusid | 2-s2.0-85041640651 | * |
dc.author.google | Jung S.-H. | * |
dc.author.google | Lee J.-J. | * |
dc.author.google | Kim J.S. | * |
dc.author.google | Min C.-K. | * |
dc.author.google | Kim K. | * |
dc.author.google | Choi Y. | * |
dc.author.google | Eom H.-S. | * |
dc.author.google | Joo Y.D. | * |
dc.author.google | Kim S.-H. | * |
dc.author.google | Kwak J.-Y. | * |
dc.author.google | Kang H.J. | * |
dc.author.google | Lee J.H. | * |
dc.author.google | Lee H.S. | * |
dc.author.google | Mun Y.-C. | * |
dc.author.google | Moon J.H. | * |
dc.author.google | Sohn S.K. | * |
dc.author.google | Park S.K. | * |
dc.author.google | Park Y. | * |
dc.author.google | Shin H.-J. | * |
dc.author.google | Yoon S.-S. | * |
dc.author.google | Korean Multiple Myeloma Working Party | * |
dc.contributor.scopusid | 문영철(7003363716) | * |
dc.date.modifydate | 20240422115947 | * |